西洛他唑联合阿司匹林或氯吡格雷双联抗血小板治疗:CSPS.com试验亚分析
CSPS.com试验亚分析纳入763例服用阿司匹林和1116例服用氯吡格雷的非心源性栓塞性高危缺血性卒中患者,随机接受单药或联合西洛他唑治疗。结果显示,氯吡格雷联合西洛他唑组主要终点事件率显著低于单药组(2.31 vs 5.19/100患者年,HR 0.447),且未增加严重出血风险;阿司匹林组联合治疗无显著差异。
要点
- 氯吡格雷联合西洛他唑显著降低缺血性卒中复发风险,且不增加出血。
- 阿司匹林联合西洛他唑未显示显著获益。
- 氯吡格雷组患者基线风险因素多于阿司匹林组。
核心结论
- 在非心源性栓塞性高危缺血性卒中患者中,西洛他唑联合氯吡格雷显著减少缺血性卒中复发且不增加出血风险。
研究设计与样本
- CSPS.com试验为多中心、开放标签、随机对照研究,纳入高危非心源性栓塞性缺血性卒中发病8至180天的患者,随机接受单药或联合西洛他唑治疗,随访0.5至3.5年,本亚分析基于基础抗血小板药物(阿司匹林或氯吡格雷)分组。
主要发现
- 氯吡格雷组中,联合治疗组主要终点事件率为2.31/100患者年,单药组为5.19/100患者年(HR 0.447,95%CI 0.258–0.774)。
- 氯吡格雷组中,严重或危及生命出血事件率联合组为0.51/100患者年,单药组为0.71/100患者年(HR 0.730,95%CI 0.206–2.588),无显著差异。
- 阿司匹林组中,联合治疗与单药治疗在主要疗效终点和安全终点上均无显著差异。
- 氯吡格雷组患者比阿司匹林组具有更多风险因素,但两组间主要疗效和 safety 终点无显著差异。
临床怎么用
- 对于非心源性栓塞性高危缺血性卒中患者,可考虑西洛他唑联合氯吡格雷进行双联抗血小板治疗以降低复发风险。
局限性
- 本研究为开放标签设计,亚分析基于基础抗血小板药物分组,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Although dual antiplatelet therapy (DAPT) with aspirin and clopidogrel reduces the recurrence of ischemic stroke while significantly increasing the bleeding events compared with monotherapy, the CSPS.com trial (Cilostazol Stroke Prevention Study combination) showed that DAPT using cilostazol was more effective without the bleeding risk. In the CSPS.com trial, aspirin or clopidogrel was used as the underlying antiplatelet drug. The effectiveness and safety of each combination were examined and clarified. METHODS: In the CSPS.com trial, a multicenter, open-label, randomized controlled study, patients with high-risk, noncardioembolic ischemic stroke 8 to 180 days after onset treated with aspirin or clopidogrel alone at the discretion of the physician in charge were recruited. Patients were randomly assigned to receive either monotherapy or DAPT using cilostazol and followed for 0.5 to 3.5 years. The primary efficacy outcome was first recurrence of ischemic stroke. The safety outcome was severe or life-threatening bleeding. The analysis was based on the underlying antiplatelet agents. RESULTS: A total of 763 patients taking aspirin and 1116 taking clopidogrel were included in the intention-to-treat analysis. Although the clopidogrel group had more risk factors than the aspirin group, the primary efficacy outcome and safety outcome did not differ significantly between the 2 groups. In the aspirin group, the primary efficacy outcome and safety outcome did not differ significantly between the DAPT group and the aspirin-monotherapy group. In the clopidogrel group, the primary end point occurred at a rate of 2.31 per 100 patient-years in the DAPT group and 5.19 per 100 patient-years in the clopidogrel-monotherapy group (hazard ratio, 0.447 [95% CI, 0.258–0.774]). Safety outcome did not differ significantly between groups (0.51 per 100 patient-years versus 0.71 per 100 patient-years, respectively; hazard ratio, 0.730 [95% CI, 0.206–2.588]). CONCLUSIONS: The combination of cilostazol and clopidogrel significantly reduced the recurrence of ischemic stroke without increasing the bleeding risk in noncardioembolic, high-risk patients. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01995370. URL: https://www.umin.ac.jp/ctr/; Unique identifier: UMIN000012180.
引用
- Hoshino H, Toyoda K, Omae K, et al. Dual Antiplatelet Therapy Using Cilostazol With Aspirin or Clopidogrel: Subanalysis of the CSPS.com Trial. Stroke. 2021. PMID: 34404237. doi:10.1161/STROKEAHA.121.034378
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。